Trial Profile

A Clinical Study of ADVM-022 for the Treatment of Patients with Diabetic Retinopathy (DR)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary)
Indications Diabetic retinopathy
Focus Adverse reactions
Sponsors Adverum Biotechnologies

Most Recent Events

12 Mar 2020 According to an Adverum Biotechnologies media release, the company expects to submit an investigational new drug application for ADVM-022 in diabetic retinopathy in the second quarter of 2020.
12 Jan 2020 According to an Adverum Biotechnologies media release, patient enrollment in this study is targeted for 2H 2020.
23 Aug 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com